Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Histoplasmosis Indication Strategy Report 2026: Histoplasma CYP51, Trials and Deals
23 July 2026
2026 Histoplasmosis strategy: epidemiology, Histoplasma CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Mucormycosis Indication Strategy Report 2026: Mucorales CYP51, Trials and Deals
23 July 2026
2026 Mucormycosis strategy: epidemiology, Mucorales CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pneumocystis pneumonia Indication Strategy Report 2026: Pneumocystis DHFR, Trials and Deals
23 July 2026
2026 Pneumocystis pneumonia strategy: epidemiology, Pneumocystis DHFR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cryptococcal meningitis Indication Strategy Report 2026: Cryptococcus CYP51, Trials and Deals
23 July 2026
2026 Cryptococcal meningitis strategy: epidemiology, Cryptococcus CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Anthrax Indication Strategy Report 2026: Anthrax protective antigen, Trials and Deals
23 July 2026
2026 Anthrax strategy: epidemiology, Anthrax protective antigen biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Tetanus Indication Strategy Report 2026: Tetanospasmin, Trials and Deals
23 July 2026
2026 Tetanus strategy: epidemiology, Tetanospasmin biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Diphtheria Indication Strategy Report 2026: Diphtheria toxin, Trials and Deals
23 July 2026
2026 Diphtheria strategy: epidemiology, Diphtheria toxin biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Botulism Indication Strategy Report 2026: Botulinum toxin, Trials and Deals
23 July 2026
2026 Botulism strategy: epidemiology, Botulinum toxin biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Leptospirosis Indication Strategy Report 2026: Leptospira LigA, Trials and Deals
23 July 2026
2026 Leptospirosis strategy: epidemiology, Leptospira LigA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Scrub typhus Indication Strategy Report 2026: Orientia DNA gyrase, Trials and Deals
23 July 2026
2026 Scrub typhus strategy: epidemiology, Orientia DNA gyrase biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Rickettsiosis Indication Strategy Report 2026: Rickettsia DNA gyrase, Trials and Deals
23 July 2026
2026 Rickettsiosis strategy: epidemiology, Rickettsia DNA gyrase biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Tularemia Indication Strategy Report 2026: Francisella LpxC, Trials and Deals
23 July 2026
2026 Tularemia strategy: epidemiology, Francisella LpxC biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…